Details of the Drug

General Information of Drug (ID: DM5SICT)

• Drug Name: Phenolphthalein
• Synonyms: phenolphthalein; 77-09-8; Phthalimetten; Phthalin; Euchessina; Phenolax; Purgophen; Espotabs; Koprol; Trilax; Laxogen; Purga; Lilo; Spulmako-lax; Feen-A-Mint Gum; Chocolax; Purgen; 3,3-Bis(4-hydroxyphenyl)phthalide; Ex-Lax; Fenolftalein; Correctol; Alophen; Medilax; Doxidan; Colax; Laxin; FemiLax; Dihydroxyphthalophenone; Phillips Gelcaps; 3,3-Bis(4-hydroxyphenyl)-1(3H)-isobenzofuranone; Lax-Pills; Evac-Q-Tabs; Evac-Q-Kwik; Evac-U-Gen; Evac-Q-Kit; 1(3H)-Isobenzofuranone, 3,3-bis(4-hydroxyphenyl)-; Phenolphtaleine; Fenolftaleina; Phenophthalein

Indication

Disease Entry	ICD 11	Status	REF
Constipation	DD91.1	Withdrawn from market	[1]

• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 318.3
  Topological Polar Surface Area (xlogp); 3.6
  Rotatable Bond Count (rotbonds); 2
  Hydrogen Bond Donor Count (hbonddonor); 2
  Hydrogen Bond Acceptor Count (hbondacc); 4
• Chemical Identifiers:
  Formula: C20H14O4
  IUPAC Name: 3,3-bis(4-hydroxyphenyl)-2-benzofuran-1-one
  Canonical SMILES: C1=CC=C2C(=C1)C(=O)OC2(C3=CC=C(C=C3)O)C4=CC=C(C=C4)O
  InChI: InChI=1S/C20H14O4/c21-15-9-5-13(6-10-15)20(14-7-11-16(22)12-8-14)18-4-2-1-3-17(18)19(23)24-20/h1-12,21-22H
  InChIKey: KJFMBFZCATUALV-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 4764
  ChEBI ID: CHEBI:34914
  CAS Number: 77-09-8
  DrugBank ID: DB04824
  TTD ID: D03FDT
  VARIDT ID: DR01166
  INTEDE ID: DR1277

Molecular Interaction Atlas of This Drug

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Multidrug resistance-associated protein 2 (ABCC2)	DTFI42L	MRP2_HUMAN	Substrate	[2]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
UDP-glucuronosyltransferase 1A1 (UGT1A1) Main DME	DEYGVN4	UD11_HUMAN	Substrate	[3]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Phenolphthalein (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Moderate	Increased risk of ventricular arrhythmias by the combination of Phenolphthalein and Ivosidenib.	Acute myeloid leukaemia [2A60]	[24]
Midostaurin	DMI6E0R	Moderate	Increased risk of ventricular arrhythmias by the combination of Phenolphthalein and Midostaurin.	Acute myeloid leukaemia [2A60]	[24]
Arn-509	DMT81LZ	Moderate	Increased risk of ventricular arrhythmias by the combination of Phenolphthalein and Arn-509.	Acute myeloid leukaemia [2A60]	[24]
Gilteritinib	DMWQ4MZ	Moderate	Increased risk of ventricular arrhythmias by the combination of Phenolphthalein and Gilteritinib.	Acute myeloid leukaemia [2A60]	[24]
Oliceridine	DM6MDCF	Moderate	Increased risk of ventricular arrhythmias by the combination of Phenolphthalein and Oliceridine.	Acute pain [MG31]	[25]
Dronedarone	DMA8FS5	Moderate	Increased risk of ventricular arrhythmias by the combination of Phenolphthalein and Dronedarone.	Angina pectoris [BA40]	[24]
Bedaquiline	DM3906J	Moderate	Increased risk of ventricular arrhythmias by the combination of Phenolphthalein and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[24]
Retigabine	DMGNYIH	Moderate	Increased risk of ventricular arrhythmias by the combination of Phenolphthalein and Retigabine.	Behcet disease [4A62]	[25]
Eribulin	DM1DX4Q	Moderate	Increased risk of ventricular arrhythmias by the combination of Phenolphthalein and Eribulin.	Breast cancer [2C60-2C6Y]	[24]
Bosutinib	DMTI8YE	Moderate	Increased risk of ventricular arrhythmias by the combination of Phenolphthalein and Bosutinib.	Breast cancer [2C60-2C6Y]	[24]
PF-04449913	DMSB068	Moderate	Increased risk of ventricular arrhythmias by the combination of Phenolphthalein and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[24]
Pasireotide	DMHM7JS	Moderate	Increased risk of ventricular arrhythmias by the combination of Phenolphthalein and Pasireotide.	Cushing syndrome [5A70]	[24]
Osilodrostat	DMIJC9X	Moderate	Increased risk of ventricular arrhythmias by the combination of Phenolphthalein and Osilodrostat.	Cushing syndrome [5A70]	[25]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of ventricular arrhythmias by the combination of Phenolphthalein and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[24]
Deutetrabenazine	DMUPFLI	Moderate	Increased risk of ventricular arrhythmias by the combination of Phenolphthalein and Deutetrabenazine.	Dystonic disorder [8A02]	[24]
Fostemsavir	DM50ILT	Moderate	Increased risk of ventricular arrhythmias by the combination of Phenolphthalein and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[24]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of ventricular arrhythmias by the combination of Phenolphthalein and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[24]
Crizotinib	DM4F29C	Moderate	Increased risk of ventricular arrhythmias by the combination of Phenolphthalein and Crizotinib.	Lung cancer [2C25]	[24]
Ceritinib	DMB920Z	Moderate	Increased risk of ventricular arrhythmias by the combination of Phenolphthalein and Ceritinib.	Lung cancer [2C25]	[24]
Osimertinib	DMRJLAT	Moderate	Increased risk of ventricular arrhythmias by the combination of Phenolphthalein and Osimertinib.	Lung cancer [2C25]	[24]
Selpercatinib	DMZR15V	Moderate	Increased risk of ventricular arrhythmias by the combination of Phenolphthalein and Selpercatinib.	Lung cancer [2C25]	[25]
Lumefantrine	DM29GAD	Moderate	Increased risk of ventricular arrhythmias by the combination of Phenolphthalein and Lumefantrine.	Malaria [1F40-1F45]	[25]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of ventricular arrhythmias by the combination of Phenolphthalein and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[24]
Vemurafenib	DM62UG5	Moderate	Increased risk of ventricular arrhythmias by the combination of Phenolphthalein and Vemurafenib.	Melanoma [2C30]	[24]
LGX818	DMNQXV8	Moderate	Increased risk of ventricular arrhythmias by the combination of Phenolphthalein and LGX818.	Melanoma [2C30]	[24]
Panobinostat	DM58WKG	Moderate	Increased risk of ventricular arrhythmias by the combination of Phenolphthalein and Panobinostat.	Multiple myeloma [2A83]	[24]
Siponimod	DM2R86O	Moderate	Increased risk of ventricular arrhythmias by the combination of Phenolphthalein and Siponimod.	Multiple sclerosis [8A40]	[24]
Romidepsin	DMT5GNL	Moderate	Increased risk of ventricular arrhythmias by the combination of Phenolphthalein and Romidepsin.	Mycosis fungoides [2B01]	[25]
Nilotinib	DM7HXWT	Moderate	Increased risk of ventricular arrhythmias by the combination of Phenolphthalein and Nilotinib.	Myeloproliferative neoplasm [2A20]	[24]
Entrectinib	DMMPTLH	Moderate	Increased risk of ventricular arrhythmias by the combination of Phenolphthalein and Entrectinib.	Non-small cell lung cancer [2C25]	[25]
Lofexidine	DM1WXA6	Moderate	Increased risk of ventricular arrhythmias by the combination of Phenolphthalein and Lofexidine.	Opioid use disorder [6C43]	[24]
Triclabendazole	DMPWGBR	Moderate	Increased risk of ventricular arrhythmias by the combination of Phenolphthalein and Triclabendazole.	Parasitic worm infestation [1F90]	[25]
Pimavanserin	DMR7IVC	Moderate	Increased risk of ventricular arrhythmias by the combination of Phenolphthalein and Pimavanserin.	Parkinsonism [8A00]	[24]
Lefamulin	DME6G97	Moderate	Increased risk of ventricular arrhythmias by the combination of Phenolphthalein and Lefamulin.	Pneumonia [CA40]	[24]
Degarelix	DM3O8QY	Moderate	Increased risk of ventricular arrhythmias by the combination of Phenolphthalein and Degarelix.	Prostate cancer [2C82]	[24]
ABIRATERONE	DM8V75C	Moderate	Increased risk of ventricular arrhythmias by the combination of Phenolphthalein and ABIRATERONE.	Prostate cancer [2C82]	[24]
Enzalutamide	DMGL19D	Moderate	Increased risk of ventricular arrhythmias by the combination of Phenolphthalein and Enzalutamide.	Prostate cancer [2C82]	[24]
Iloperidone	DM6AUFY	Moderate	Increased risk of ventricular arrhythmias by the combination of Phenolphthalein and Iloperidone.	Schizophrenia [6A20]	[24]
Asenapine	DMSQZE2	Moderate	Increased risk of ventricular arrhythmias by the combination of Phenolphthalein and Asenapine.	Schizophrenia [6A20]	[24]
LEE011	DMMX75K	Moderate	Increased risk of ventricular arrhythmias by the combination of Phenolphthalein and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[24]
Vandetanib	DMRICNP	Moderate	Increased risk of ventricular arrhythmias by the combination of Phenolphthalein and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[24]
Triptorelin	DMTK4LS	Moderate	Increased risk of ventricular arrhythmias by the combination of Phenolphthalein and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[24]
Pitolisant	DM8RFNJ	Moderate	Increased risk of ventricular arrhythmias by the combination of Phenolphthalein and Pitolisant.	Somnolence [MG42]	[24]
Telavancin	DM58VQX	Moderate	Increased risk of ventricular arrhythmias by the combination of Phenolphthalein and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[24]
Lenvatinib	DMB1IU4	Moderate	Increased risk of ventricular arrhythmias by the combination of Phenolphthalein and Lenvatinib.	Thyroid cancer [2D10]	[24]
Cabozantinib	DMIYDT4	Moderate	Increased risk of ventricular arrhythmias by the combination of Phenolphthalein and Cabozantinib.	Thyroid cancer [2D10]	[24]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Biliary excretion of phenolphthalein sulfate in rats. Pharmacology. 2003 Aug;68(4):177-82.
• [3] Inhibition of UDP-glucuronyltransferase activity in rat liver microsomes by pyrimidine derivatives. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1995 Nov;112(3):321-5.
• [4] Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
• [5] Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
• [6] Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
• [7] UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
• [8] Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
• [9] Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
• [10] Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
• [11] Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
• [12] Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
• [13] Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
• [14] Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7.
• [15] Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov;39(11):2155-61.
• [16] Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 2011 Sep 7;50(1):179-207.
• [17] Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2. Oncol Lett. 2016 Sep;12(3):2107-2114.
• [18] Multidrug resistance associated protein 2 mediates transport of prostaglandin E2. Liver Int. 2006 Apr;26(3):362-8.
• [19] Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008 Oct 4;6:55.
• [20] Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein. Biochem Pharmacol. 2004 Aug 15;68(4):791-8.
• [21] Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7.
• [22] Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63.
• [23] Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS One. 2015 Jul 1;10(7):e0130727.
• [24] Canadian Pharmacists Association.
• [25] Cerner Multum, Inc. "Australian Product Information.".